Patents by Inventor John Steven Whitaker

John Steven Whitaker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HIGHLY CONCENTRATED LOW VISCOSITY MASP-2 INHIBITORY ANTIBODY FORMULATIONS, KITS, AND METHODS
    Publication number: 20230226178
    Abstract: The present invention relates to stable, high-concentration low-viscosity formulations of MASP-2 inhibitory antibodies, kits comprising the formulations and therapeutic methods using the formulations and kits for inhibiting the adverse effects of MASP-2 dependent complement activation.
    Type: Application
    Filed: February 28, 2023
    Publication date: July 20, 2023
    Inventors: Gregory A. Demopulos, Kenneth M. Ferguson, William Joseph Lambert, John Steven Whitaker
  • Highly concentrated low viscosity MASP-2 inhibitory antibody formulations, kits, and methods
    Patent number: 11628217
    Abstract: The present invention relates to stable, high-concentration low-viscosity formulations of MASP-2 inhibitory antibodies, kits comprising the formulations and therapeutic methods using the formulations and kits for inhibiting the adverse effects of MASP-2 dependent complement activation.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: April 18, 2023
    Assignee: OMEROS CORPORATION
    Inventors: Gregory A. Demopulos, Kenneth M. Ferguson, William Joseph Lambert, John Steven Whitaker
  • Methods of Inhibiting MASP-2 for the Treatment and/or Prevention of Coronavirus-induced Acute Respiratory Distress Syndrome
    Publication number: 20210292436
    Abstract: In one aspect, the invention provides methods for treating, inhibiting, alleviating, or preventing acute respiratory distress syndrome, pneumonia, or some other pulmonary or other manifestation of coronavirus infection, such as thrombosis, in a mammalian subject infected with coronavirus, such as SARS-CoV-2. The methods comprise the step of administering to a subject infected with coronavirus an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In one embodiment, the MASP-2 inhibitory agent is a MASP-2 monoclonal antibody, or fragment thereof that specifically binds to a portion of SEQ ID NO:6. In one embodiment, the MASP-2 inhibitory agent is a small molecule MASP-2 inhibitory compound.
    Type: Application
    Filed: March 5, 2021
    Publication date: September 23, 2021
    Inventors: Gregory A. Demopulos, Tineka J. Quinton, John Steven Whitaker
  • HIGHLY CONCENTRATED LOW VISCOSITY MASP-2 INHIBITORY ANTIBODY FORMULATIONS, KITS, AND METHODS OF TREATING SUBJECTS SUFFERING FROM ATYPICAL HEMOLYTIC SYNDROME
    Publication number: 20190062455
    Abstract: The present invention relates to therapeutic methods of using stable, high-concentration low-viscosity formulations of MASP-2 inhibitory antibodies, and kits comprising the formulations for treating subjects suffering from atypical hemolytic uremic syndrome (aHUS).
    Type: Application
    Filed: August 21, 2018
    Publication date: February 28, 2019
    Inventors: Gregory A. Demopulos, Kenneth M. Ferguson, William Joseph Lambert, John Steven Whitaker
  • HIGHLY CONCENTRATED LOW VISCOSITY MASP-2 INHIBITORY ANTIBODY FORMULATIONS, KITS, AND METHODS
    Publication number: 20180153988
    Abstract: The present invention relates to stable, high-concentration low-viscosity formulations of MASP-2 inhibitory antibodies, kits comprising the formulations and therapeutic methods using the formulations and kits for inhibiting the adverse effects of MASP-2 dependent complement activation.
    Type: Application
    Filed: August 30, 2017
    Publication date: June 7, 2018
    Inventors: Gregory A. Demopulos, Kenneth M. Ferguson, William Joseph Lambert, John Steven Whitaker
  • Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
    Patent number: 6943166
    Abstract: The present invention relates to highly selective phosphodieterase (PDE) enzyme inhibitors and to their use in pharmaceutical articles of manufacture. In particular, the present invention relates to potent inhibitors of cyclic guanosine 3?,5?-monophosphate specific phosphodiesterase type 5 (PDE5) that when incorporated into a pharmaceutical product at about 1 to about 20 mg unit dosage are useful for the treatment of sexual dysfunction.
    Type: Grant
    Filed: April 26, 2000
    Date of Patent: September 13, 2005
    Assignee: Lilly ICOS LLC.
    Inventors: William Ernest Pullman, John Steven Whitaker
  • Unit dosage form
    Publication number: 20040058929
    Abstract: The present invention relates to highly selective phosphodiesterase (PDE) enzyme inhibitors and to their use in pharmaceutical articles of manufacture. In particular, the present invention relates to potent inhibitors of cyclic guanosine 3′,5′-monophosphate specific phosphodiesterase type 5 (PDES) that when incorporated into a pharmaceutical product at about 1 to about 20 mg unit dosage are useful for the treatment of sexual dysfunction.
    Type: Application
    Filed: September 12, 2003
    Publication date: March 25, 2004
    Inventors: William Ernest Pullman, John Steven Whitaker